Doe
Thu, Aug-21-03, 06:10
Anyone here know anything about these trials .. ?
<<snip>> The trials initially will focus on individuals with
the autoimmune disease lupus, who are extremely sensitive to
the sun. <<snip>>
UNIVERSITY OF FLORIDA AND PROCTER & GAMBLE TEAM UP AGAINST
SKIN CANCER
Feb. 11, 2002 Contact Information
--------------------------------------------------------------
-------------
------
GAINESVILLE, Fla. --- The University of Florida and
Procter & Gamble today announced they have joined forces
to advance research on Photoprotective Iron Chelator
Technology, which was developed by P&G and shows promise
for preventing or reducing the harmful effects of the sun,
particularly skin cancer.
Preliminary research has shown that, in combination with the
appropriate sunscreen, Photoprotective Iron Chelator
Technology, or PICT, may have the potential to decrease the
number of individuals who develop skin cancer by greatly
delaying or preventing tumor onset. It may also reduce the
number of tumors in those who do develop skin cancer. The
safety and efficacy of PICT must be demonstrated in clinical
trials, and the product will ultimately require review and
approval by the Food and Drug Administration.
“When ultraviolet light penetrates the skin it forms oxygen
radicals which, in the presence of iron, can cause skin
wrinkling, sunburn and cancer,” said Don Bissett, a P&G skin
care research fellow, whose more than six years of research
resulted in PICT. “The P&G iron chelator binds to iron so
that it can no longer cause this reaction.”
P&G and the University of Florida Research Foundation have
formed a new company called ChelaDerm to continue the
development of the technology and seek FDA approval. P&G will
contribute a royalty-free, exclusive license of the PICT
patents to the new company, while the research foundation will
underwrite independent clinical trials and provide ChelaDerm
with access to UF personnel and resources through a management
services contract. The research foundation is a private,
not-for-profit support organization that facilitates the
transfer of university technology from the laboratory to the
marketplace.
PICT arose from P&G’s substantial commitment to skin-care
research. Because P&G is not able to devote resources to
commercialize all of its more than 27,000 patents, the company
occasionally seeks partners to advance technologies that are
not a strategic fit with its current product development
activities. P&G markets 250 brands to five billion consumers
in 130 countries and invests nearly $2 billion a year research
and development.
Dr. Raymond Bergeron, a graduate research professor of
medicinal chemistry and eminent scholar in drug
development in the UF College of Pharmacy, is one of the
world's leading experts on iron chelators. Bergeron has
spent more than two decades studying iron chelators and is
the author of numerous publications on the subject. His
expertise in drug discovery and development led to the
company’s decision to pursue a partnership with UF.
“2-furildioxime, or FDO, the active ingredient in PICT, in
combination with a sunscreening agent, has the potential to
offer both improved prevention of sunburn and a unique means
of delaying or preventing the development of skin cancer,”
Bergeron said, adding that more than a million Americans
develop skins cancer annually.
“Consumers have become increasingly aware of the dangers of
unprotected exposure to ultraviolet radiation,” said Tom
Minnick, P&G’s director of external business development and
president of ChelaDerm. “We’re excited to work with the UF
Research Foundation in an effort to develop a new sun care
product to address both the short-term effects of sun
exposure, such as sunburn, as well as the long-term effects,
including skin cancer risk and premature aging of the skin.”
Initial clinical trials will confirm the safety of FDO and
determine what combinations of FDO and sunscreens are most
effective in preventing skin damage. The trials initially will
focus on individuals with the autoimmune disease lupus, who
are extremely sensitive to the sun.
“ChelaDerm offers an unprecedented opportunity for the
University of Florida and P&G to pool their extensive
intellectual and scientific resources in an effort to
alleviate the negative impact of ultraviolet sun
exposure,” said Win Phillips, UF’s vice president for
research. “Facilitating the transfer of this kind of
technology from the laboratory to the marketplace in a
timely manner is exactly what the UF Research Foundation was
established to do.”
-30-
--------------------------------------------------------------
-------------
------
Sources: Joseph Kays, (352) 392-8229, joekays@ufl.edu Caroline
Charles, Northlich PR for P&G, (513) 762-5571
--------------------------------------------------------------
-------------
------
Who loves ya. Tom Jesus Was A Vegetarian!
http://jesuswasavegetarian.7h.com Man Is A Herbivore!
http://pages.ivillage.com/ironjustice/manisaherbivore DEAD
PEOPLE WALKING
http://pages.ivillage.com/ironjustice/deadpeoplewalking
<<snip>> The trials initially will focus on individuals with
the autoimmune disease lupus, who are extremely sensitive to
the sun. <<snip>>
UNIVERSITY OF FLORIDA AND PROCTER & GAMBLE TEAM UP AGAINST
SKIN CANCER
Feb. 11, 2002 Contact Information
--------------------------------------------------------------
-------------
------
GAINESVILLE, Fla. --- The University of Florida and
Procter & Gamble today announced they have joined forces
to advance research on Photoprotective Iron Chelator
Technology, which was developed by P&G and shows promise
for preventing or reducing the harmful effects of the sun,
particularly skin cancer.
Preliminary research has shown that, in combination with the
appropriate sunscreen, Photoprotective Iron Chelator
Technology, or PICT, may have the potential to decrease the
number of individuals who develop skin cancer by greatly
delaying or preventing tumor onset. It may also reduce the
number of tumors in those who do develop skin cancer. The
safety and efficacy of PICT must be demonstrated in clinical
trials, and the product will ultimately require review and
approval by the Food and Drug Administration.
“When ultraviolet light penetrates the skin it forms oxygen
radicals which, in the presence of iron, can cause skin
wrinkling, sunburn and cancer,” said Don Bissett, a P&G skin
care research fellow, whose more than six years of research
resulted in PICT. “The P&G iron chelator binds to iron so
that it can no longer cause this reaction.”
P&G and the University of Florida Research Foundation have
formed a new company called ChelaDerm to continue the
development of the technology and seek FDA approval. P&G will
contribute a royalty-free, exclusive license of the PICT
patents to the new company, while the research foundation will
underwrite independent clinical trials and provide ChelaDerm
with access to UF personnel and resources through a management
services contract. The research foundation is a private,
not-for-profit support organization that facilitates the
transfer of university technology from the laboratory to the
marketplace.
PICT arose from P&G’s substantial commitment to skin-care
research. Because P&G is not able to devote resources to
commercialize all of its more than 27,000 patents, the company
occasionally seeks partners to advance technologies that are
not a strategic fit with its current product development
activities. P&G markets 250 brands to five billion consumers
in 130 countries and invests nearly $2 billion a year research
and development.
Dr. Raymond Bergeron, a graduate research professor of
medicinal chemistry and eminent scholar in drug
development in the UF College of Pharmacy, is one of the
world's leading experts on iron chelators. Bergeron has
spent more than two decades studying iron chelators and is
the author of numerous publications on the subject. His
expertise in drug discovery and development led to the
company’s decision to pursue a partnership with UF.
“2-furildioxime, or FDO, the active ingredient in PICT, in
combination with a sunscreening agent, has the potential to
offer both improved prevention of sunburn and a unique means
of delaying or preventing the development of skin cancer,”
Bergeron said, adding that more than a million Americans
develop skins cancer annually.
“Consumers have become increasingly aware of the dangers of
unprotected exposure to ultraviolet radiation,” said Tom
Minnick, P&G’s director of external business development and
president of ChelaDerm. “We’re excited to work with the UF
Research Foundation in an effort to develop a new sun care
product to address both the short-term effects of sun
exposure, such as sunburn, as well as the long-term effects,
including skin cancer risk and premature aging of the skin.”
Initial clinical trials will confirm the safety of FDO and
determine what combinations of FDO and sunscreens are most
effective in preventing skin damage. The trials initially will
focus on individuals with the autoimmune disease lupus, who
are extremely sensitive to the sun.
“ChelaDerm offers an unprecedented opportunity for the
University of Florida and P&G to pool their extensive
intellectual and scientific resources in an effort to
alleviate the negative impact of ultraviolet sun
exposure,” said Win Phillips, UF’s vice president for
research. “Facilitating the transfer of this kind of
technology from the laboratory to the marketplace in a
timely manner is exactly what the UF Research Foundation was
established to do.”
-30-
--------------------------------------------------------------
-------------
------
Sources: Joseph Kays, (352) 392-8229, joekays@ufl.edu Caroline
Charles, Northlich PR for P&G, (513) 762-5571
--------------------------------------------------------------
-------------
------
Who loves ya. Tom Jesus Was A Vegetarian!
http://jesuswasavegetarian.7h.com Man Is A Herbivore!
http://pages.ivillage.com/ironjustice/manisaherbivore DEAD
PEOPLE WALKING
http://pages.ivillage.com/ironjustice/deadpeoplewalking